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Inherited missense variants that affect GFI1B 
function do not necessarily cause bleeding diatheses
Several types of GFI1B variants have been identified in
patients with inherited bleeding and platelet disorders.
This includes dominant-negative truncating variants
affecting DNA binding,1-4 missense variants of which the
molecular mechanism is unclear,5-7 and variants changing
the amount and ratio of GFI1B isoforms (Online
Supplementary Figure S1).7,8 The severity of the bleeding
disorder may differ depending on the type of variant, but
frequent abnormalities include macrothrombocytopenia,
a reduction in alpha (α)-granule numbers, and platelet
CD34 expression. In this study, we performed a molecu-
lar and/or clinicopathological characterization of eight
GFI1B variants located in non-DNA binding domains
(Online Supplementary Figure S1). These variants had been
previously identified by the NIHR BioResource rare dis-
ease study in cases with an assumed inherited bleeding or
platelet disorder.9 Molecular characterization was not
performed for D23N since the minor allele frequency in
the gnomAD database was considered too high for a
causal variant. From the characterization of the other
variants, we can conclude that, although some have a
clear effect on GFI1B function, they are not necessarily
sufficient to cause a bleeding predisposition on their
own.
We previously used the megakaryoblast cell line MEG-
01 to study the effect of GFI1B and the proven pathogen-
ic GFI1B-Q287* variant on cell expansion. In expansion-
competition cultures containing transduced and non-
transduced cells, MEG-01 cells ectopically expressing
GFI1B were overgrown by non-transduced cells, while
the opposite was observed following expression of
GFI1B-Q287* (Figure 1).10 Thus, forced GFI1B expression
inhibits MEG-01 cell expansion whereas dominant-nega-
tive GFI1B-Q287* results in enhanced expansion. The lat-
ter is in line with elevated megakaryocyte numbers
observed in a bone marrow specimen of an individual
presenting the GFI1B p.Q287* variant.1 To investigate the
functional effect of GFI1B variants, they were retrovirally
expressed  in MEG-01 cells and tested in the expansion-
competition culture described above. GFI1B and GFI1B-
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Figure 1. GFI1B variants have distinct effects on MEG-01 expansion. Expansion competition
cultures of MEG-01 cells transduced with flag-tagged GFI1B variants. (A) G139S. (B) G198S.
(C) R190W. (D) C168F. (E) Q89fs. (F) H181Y. (G) R184P. GFI1B-Q287*-flag, GFI1B-p37-flag
wild type (WT), and empty vector (EV) served as controls. Fold change of GFP% to GFP% at
day 5 (first GFP measurement) is presented on the y-axis. Results show Mean±Standard
Error of Mean, and two-tailed paired t-tests were performed on day 26 to determine statis-
tical significance. *P<0.05; **P<0.01. Of note, all MEG-01 transduced cells showed
increased GFI1B mRNA expression indicating expression of the retroviral vector (Online
Supplementary Figure S2). n: number of experiments performed.
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Q287* were used as references. Two variants, one in the
intermediate domain (G139S) and one in zinc finger (znf)
2 (G198S), did not affect the inhibitory function of wild-
type (WT) GFI1B on MEG-01 proliferation (Figure 1A and
B). The R190W variant, located between znf1 and znf2,
made the protein less effective at inhibiting MEG-01 pro-
liferation (Figure 1C), while both the znf1 variant C168F
and the truncated variant Q89fs made the protein com-
pletely inactive (Figure 1D and E). Interestingly, expres-
sion of znf1 H181Y and R184P variants resulted in
increased MEG-01 cell proliferation, although to a lesser
extent than cells expressing GFI1B-Q287* (Figure 1F and
G). To further study H181Y and R184P, we introduced
these variants separately in GFI1B-Q287*. This led to par-
tial inhibition of the growth stimulating effect of GFI1B-
Q287* (Figure 2A and B), indicating that amino acids
H181 and R184 are important for the effect of GFI1B-
Q287* on MEG-01 proliferation. These findings clearly
demonstrate that different variants distinctively impact
the qualitative function of GFI1B, and that znf1 is impor-
tant in regulating MEG-01 proliferation.
The increased MEG-01 expansion caused by GFI1B-
H181Y and GFI1B-R184P suggests that these variants,
like GFI1B-Q287*, act in a dominant-negative manner.
However, the molecular mechanism might be different,
because these variants are not located in the DNA bind-
ing domain in contrast to GFI1B-Q287*. GFI1B is a
repressive transcription factor that inhibits its own tran-
scription and that of its paralog GFI1.11,12 GFI1B-Q287*
does not possess this repressive function.1 To study if the
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Figure 2. Functional effect of GFI1B variants H181Y and R184P.
(A and B) Expansion competition cultures of MEG-01 cells trans-
duced with flag-tagged GFI1B-H181Y+Q287* (A) or GFI1B-
R184P-Q287* (B). Empty vector (EV) and GFI1B-Q287*-flag
transduced cells served as controls. (C) Dual luciferase reporter
assays in HEK293FT cells transfected with Renilla luciferase con-
struct, Gfi1 promoter Firefly luciferase construct, and empty vec-
tor (EV), wild-type GFI1B-p37-flag (WT-p37), wild-type GFI1B-p32-
flag (WT-p32, lacking coding exon 4 and, therefore, amino acids
171-216 corresponding to zinc finger 1 and 2), or GFI1B-flag vari-
ants. Firefly/Renilla luciferase ratios are normalized to EV trans-
fected cells. Results show Mean±Standard Deviation, (SD) and
two-tailed paired t-tests were performed to determine statistical
significance between WT-p37 and the other conditions.
Corresponding western blots showing expression of the flag-
tagged GFI1B proteins and the GAPDH loading control are shown
below the graph. (D) 5’UTR GFI1B expression in GFP positive cells
from MEG-01 expansion competition cultures, FACS-sorted 23
days after transduction. GFI1B expression is normalized to
GAPDH expression. Results show Mean±SD, and two-tailed
paired t-tests were performed to determine statistical signifi-
cance. (E) Expansion competition cultures of MEG-01 cells trans-
duced with flag-tagged GFI1B-H181Y+P2A, or GFI1B-R184P-P2A.
EV transduced cells were taken along as reference.  *P<0.05;
**P<0.01; ***P<0.001. n: number of experiments performed;
UTR: untranslated region.
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variants affect the repressive function of GFI1B, we per-
formed gene reporter assays using the Gfi1 promoter.
Remarkably, all tested GFI1B missense variants, including
GFI1B-H181Y and GFI1B-R184P, repressed the Gfi1 pro-
moter to a similar extent as WT GFI1B (Figure 2C).
However, results obtained in transient gene repression
assays may not reflect effects on endogenous target
genes. Therefore we analyzed the effects of GFI1B-
H181Y and GFI1B-R184P on endogenous GFI1B expres-
sion. WT GFI1B, GFI1B-Q287*, GFI1B-H181Y, and
GFI1B-R184P were expressed in MEG-01 cells, followed
by endogenous GFI1B mRNA expression analysis. In line
with earlier reports, WT GFI1B inhibited endogenous
GFI1B expression.13 In contrast, GFI1B-Q287*, as well as
GFI1B-H181Y and GFI1B-R184P, did not repress endoge-
nous GFI1B expression to the same extent as WT GFI1B
(Figure 2D). This indicates that not only the DNA binding
znfs, but also amino acids H181 and R184 are required
for efficient repression of endogenous GFI1B.
The LSD1-RCOR1-HDAC co-repressor complex is one
of the main epigenetic regulatory complexes recruited by
GFI1B to induce transcriptional repression. To study
whether GFI1B-H181Y-induced and GFI1B-R184P-
induced MEG-01 expansion depends on an interaction
with this complex, we co-introduced a P2A mutation in
the GFI1B-H181Y or GFI1B-R184P variants. The P2A
mutation in the N-terminal SNAG domain of GFI1B abro-
gates its interaction with LSD114 and nullifies the
inhibitory effect of WT GFI1B and stimulatory effect of
GFI1B-Q287* on MEG-01 proliferation.10 Expression of
the P2A-H181Y and P2A-R184P double mutants resulted
in expansion rates similar to those of empty vector trans-
duced cells (Figure 2E). This strongly suggests that
H181Y and R184P variants require the LSD1 interaction
to exert their stimulating effect on MEG-01 expansion. 
The functional data were subsequently correlated with
clinical data and laboratory features of patients’ samples
to improve classification of the GFI1B variants according
to the guidelines of the American College of Medical
Genetics and genomics (ACMG)15 (Online Supplementary
Table S1). A minimal set of genetic, clinical and laborato-
ry features has already been published by Chen et al.9
(Online Supplementary Table S1). For this study, we
expanded clinical and laboratory phenotype studies for
the H181Y and R184P variants, because these GFI1B vari-
ants had similar effects on function in the MEG-01 cell
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Figure 3. Pedigrees for families harboring
GFI1B variants H181Y (A) and R184P (B). The
propositus (arrow) and the family members
with signs of pathological bleeding are indicat-
ed with a black filled symbol. Males are indi-
cated with squares, and females with circles.
GFI1B variant status, patient identifier, GFI1B
variant status, platelet count (PLT), CD34
expression, and the International Society on
Thrombosis and Hemostasis Bleeding
Assessment Tool (ISTH-BAT) score are indicat-
ed for each patient. Normal range for the 
ISTH-BAT score is <4 in adult males, <6 in
adult females, and <3 in children. P5.4 has
less hemostatic challenges than the other sib-
lings. ND: not determined. Additional clinical
and laboratory data obtained in patients' sam-
ples are available  in Online Supplementary
Table S1. 
A
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models as the proven pathogenic GFI1B-Q287* variant.
In addition, we performed clinical and laboratory pheno-
type studies for R190W variant carriers.
The variants G139S and G198S were classified as
‘Benign’ as they showed similar inhibition of MEG-01
expansion to WT GFI1B, and have a relatively high minor
allele frequency in gnomAD. Furthermore, the thrombo-
cytopenia in patient P9 with G198S was explained by a
pathogenic ACTN1 variant (p.R46Q).16 Variants R190W,
C168F and Q89fs did not inhibit MEG-01 expansion to
the same extent as WT GFI1B (loss of function effect).
R190W platelets were weakly CD34-positive, but
R190W in patients P8.1 and P8.2 did not co-segregate
with bleeding or result in abnormal α-granules (Online
Supplementary Table S1 and Online Supplementary Figures
S3-S5). Moreover, patient P7 with the same R190W vari-
ant was explained by a pathogenic variant in WAS
(p.R364*), resulting in a ‘Benign’ classification for R190W.
Patient P4 with a homozygous C168F variant suffered
from clinical bleeding symptoms with thrombocytopenia
and platelet aggregation dysfunction. Unlike P4, het-
erozygous C168F patients studied by Rabbolini et al. only
displayed macrothrombocytopenia with platelet CD34
expression (partial effect on the phenotype).7 C168F is
predicted to disrupt znf1 structure and thereby GFI1B
function.9 This was confirmed in functional experiments
performed here (Figure 1D) and by Rabbolini et al. show-
ing that C168F disrupts the repressive function of GFI1B
gene expression.7 C168F was classified as a ‘variant of
unknown significance’ (VUS); further studies in the
affected patient or of family members were not possible.
A 90-year old woman (deceased) carrying the Q89fs vari-
ant and without affected siblings had had mild thrombo-
cytopenia with bleeding, platelet dysfunction and signif-
icantly reduced α-granule numbers; a phenotype very
similar to previously described GFI1B pathogenic variants
(Online Supplementary Table S1 and Online Supplementary
Figure S5).1,2,4 The Q89fs variant does not repress the Gfi1
promoter to the same degree as WT GFI1B and the mis-
sense variants. However, it must be noted that we could
only detect the truncated protein after proteasome inhi-
bition, suggesting it is unstable (Online Supplementary
Figure S6). If this is also the case in primary patient cells,
the Q89fs variant would lead to haploinsufficiency. This
variant was classified as VUS.
The R184P and H181Y variants stimulated MEG-01
proliferation and failed to repress endogenous GFI1B
expression in a similar way to the pathogenic Q287* vari-
ant. These missense variants were absent from the
gnomAD database and co-segregation studies were per-
formed (Figure 3). Both the propositus (P6.1) and her
father (P6.2), who are carriers of R184P, showed a small
number of hypogranular platelets and platelet CD34
expression (Online Supplementary Table S1 and Online
Supplementary Figures S3 and S4). P6.1 had a normal
platelet count whereas her father (P6.2) had mild throm-
bocytopenia. Importantly, neither parent had clinical
bleeding symptoms or platelet dysfunction (Online
Supplementary Table S1 and Online Supplementary Figure
S3A). Following ACMG criteria, the R184P variant was
classified as VUS. For the propositus (P5.1) with the
H181Y variant, three affected relatives (P5.2, P5.4-5) and
one non-affected (P5.3) relative were screened and the
variant co-segregated with clinical bleeding symptoms,
platelet dysfunction and CD34-positive platelets (Online
Supplementary Table S1 and Online Supplementary Figure
S3). Affected individuals P5.1 and P5.2 had normal
platelet counts with few large platelets and a significant
reduction in α-granules (Online Supplementary Table S1
and  Online Supplementary Figures S4 and S5). The func-
tional and segregation data suggest that the H181Y vari-
ant is the cause of bleeding and platelet dysfunction but
does not result in thrombocytopenia. Following ACMG
guidelines, H181Y was classified as a VUS (Online
Supplementary Table S1). 
We conclude that Q89fs, C168F, H181Y, and R184P
affect GFI1B function, but are not necessarily sufficient to
cause bleedings on their own. However, their identifica-
tion and documentation, even when classified as VUS,
will help to distinguish pathological from non-pathologi-
cal GFI1B variants and increase our understanding of
GFI1B functional domains. The identification of addition-
al patients with similar variants will be essential to clarify
their exact role in platelet phenotypes and bleeding.
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